Genmab A/S (Germany) Performance

GE9 Stock  EUR 270.50  4.40  1.60%   
On a scale of 0 to 100, Genmab A/S holds a performance score of 8. The company retains a Market Volatility (i.e., Beta) of 0.0912, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab A/S's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab A/S is expected to be smaller as well. Please check Genmab A/S's information ratio, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Genmab A/S's current trending patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Genmab A/S reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1
Can Genmab A S Depositary Receipt stock withstand economic slowdown - July 2025 Analyst Calls Daily Stock Trend Watchlist - newser.com
11/12/2025
2
Genmab Valuation in Focus After Recent Share Price Pullback - Yahoo Finance
11/18/2025
3
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami - Yahoo Finance UK
11/24/2025
4
Merus Acquired by Genmab, Leadership Changes Announced - TipRanks
12/12/2025
5
Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline - TipRanks
12/29/2025
6
Genmab Valuation Check As Anthropic AI Alliance Supports Late Stage Pipeline Progress - simplywall.st
01/15/2026
7
Genmab s Future Potential Underappreciated by Market - Yahoo Finance UK
01/21/2026
8
GENMAB AS Stands Out as a Peter Lynch-Style GARP Investment - Chartmill
01/29/2026
  

Genmab A/S Relative Risk vs. Return Landscape

If you would invest  24,520  in Genmab AS on November 4, 2025 and sell it today you would earn a total of  2,970  from holding Genmab AS or generate 12.11% return on investment over 90 days. Genmab AS is currently producing 0.2124% returns and takes up 2.1019% volatility of returns over 90 trading days. Put another way, 18% of traded stocks are less volatile than Genmab, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Genmab A/S is expected to generate 2.81 times more return on investment than the market. However, the company is 2.81 times more volatile than its market benchmark. It trades about 0.1 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.

Genmab A/S Target Price Odds to finish over Current Price

The tendency of Genmab Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 270.50 90 days 270.50 
about 44.38
Based on a normal probability distribution, the odds of Genmab A/S to move above the current price in 90 days from now is about 44.38 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Genmab A/S has a beta of 0.0912. This usually indicates as returns on the market go up, Genmab A/S average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Genmab AS will be expected to be much smaller as well. Additionally Genmab AS has an alpha of 0.1171, implying that it can generate a 0.12 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Genmab A/S Price Density   
       Price  

Predictive Modules for Genmab A/S

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genmab A/S. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
270.70272.80274.90
Details
Intrinsic
Valuation
LowRealHigh
271.40273.50275.60
Details
Naive
Forecast
LowNextHigh
265.14267.24269.34
Details
Earnings
Estimates (0)
LowProjected EPSHigh
1.281.411.56
Details

Genmab A/S Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Genmab A/S is not an exception. The market had few large corrections towards the Genmab A/S's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genmab AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genmab A/S within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.12
β
Beta against Dow Jones0.09
σ
Overall volatility
13.45
Ir
Information ratio 0.04

Genmab A/S Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genmab A/S for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genmab A/S can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Genmab A/S is unlikely to experience financial distress in the next 2 years
Latest headline from news.google.com: GENMAB AS Stands Out as a Peter Lynch-Style GARP Investment - Chartmill

Genmab A/S Fundamentals Growth

Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab A/S, and Genmab A/S fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.

About Genmab A/S Performance

By analyzing Genmab A/S's fundamental ratios, stakeholders can gain valuable insights into Genmab A/S's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab A/S has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab A/S has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 26.42  25.10 
Return On Tangible Assets 0.23  0.24 
Return On Capital Employed 0.15  0.16 
Return On Assets 0.15  0.16 
Return On Equity 0.19  0.20 

Things to note about Genmab A/S performance evaluation

Checking the ongoing alerts about Genmab A/S for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab A/S help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Genmab A/S is unlikely to experience financial distress in the next 2 years
Latest headline from news.google.com: GENMAB AS Stands Out as a Peter Lynch-Style GARP Investment - Chartmill
Evaluating Genmab A/S's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Genmab A/S's stock performance include:
  • Analyzing Genmab A/S's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab A/S's stock is overvalued or undervalued compared to its peers.
  • Examining Genmab A/S's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Genmab A/S's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab A/S's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Genmab A/S's stock. These opinions can provide insight into Genmab A/S's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Genmab A/S's stock performance is not an exact science, and many factors can impact Genmab A/S's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Genmab Stock analysis

When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency